Grail Jun 2, 2022 Grail, AstraZeneca Partner on Companion Dx for Oncology Drugs May 31, 2022 Grail, Veterans Affairs to Evaluate Galleri Cancer Early Detection Test May 27, 2022 Guardant Health Files Motions to Dismiss, Change Venue in Illumina Patent Lawsuit May 16, 2022 Intermountain Healthcare Rolling Out Galleri Multi-Cancer Early Detection Test in Pilot Program Premium Feb 15, 2022 Point32Health to Offer Grail Cancer Early Detection Test Under Pilot Program Jan 11, 2022 Illumina Touts New Partnerships, Sequencing Technology at JP Morgan Healthcare Conference Jan 10, 2022 Grail Partners With Premier's PINC AI to Improve Patient Access to Blood-Based Multi-Cancer Test Dec 30, 2021 Top 10 Precision Oncology Articles in 2021: Liquid Biopsy, Difficult Reimbursement, TMB Debates Sep 20, 2021 Grail Gets NY State Department of Health Approval for Galleri Multicancer Test Aug 18, 2021 Illumina Acquires Grail Despite Ongoing Regulatory Scrutiny Jun 4, 2021 Grail Launches Galleri Cancer Early Detection Test, Backed by First PATHFINDER Interventional Data Premium Apr 15, 2021 Grail Cancer Early Detection Test Performance Holds Steady as Q2 Launch Approaches Premium Mar 19, 2021 In Brief This Week: Merck, Clovis Oncology, Grail, GenomOncology, Veracyte, Amoy Diagnostics Feb 8, 2021 Strata Oncology Launches Large Study Eyeing Competitive Cancer Monitoring, Drug Selection Test Space Premium Jan 11, 2021 Multi-Cancer Molecular Screening Assays Primed for Clinical Implementation in 2021 Premium Jan 11, 2021 Grail Inks Deals With Amgen, AstraZeneca, Bristol Myers Squibb for MRD Test Development Nov 30, 2020 Grail Inks Deal With UK National Health Service to Offer Cancer Screening Blood Test in 2021 Sep 21, 2020 Illumina to Acquire Grail for $8B in Cash and Stock Apr 29, 2020 Pan-Cancer Screening Tests Report First Performance Numbers in Undiagnosed Cohorts Premium Jan 28, 2020 Precision Oncology Data From ASCO's Gastrointestinal Cancer Symposium 2020 Load More Breaking News Flare Therapeutics Raises $123M in Oversubscribed Series B Funding Round William Blair Initiates Coverage of MDxHealth With Outperform Rating White House Report Outlines Goals to Advance Genomic Research, Precision Therapy Development In Brief This Week: Fore Biotherapeutics, RayzeBio, Gilead Sciences, Atossa Therapeutics Bayer to Assess Nubeqa in High-Risk, Early-Stage Hormone-Sensitive Prostate Cancer BridgeBio Begins Phase I/II Study of SHP2 Inhibitor, Opdivo in KRAS-Mutant Solid Tumors
